Amgen Announces Its Registration Statement on Form S-3 Has Been Declared Effective
OAKS, Calif - May 31, 2002 - Amgen Inc. (Nasdaq:AMGN) announced
today that a Registration Statement on Form S-3 relating to the
resale by the holders of Amgen's Liquid Yield Option Notes
due 2032 (the "LYONs") and shares of Amgen common stock
issuable upon conversion and/or redemption of the LYONs has been
declared effective by the Securities and Exchange Commission. Amgen's
issuance of the LYONs, which raised approximately $2.8 billion in
gross proceeds, was completed on March 1, 2002.
This press release shall not constitute either an
offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state.
This news release contains forward-looking statements
that involve significant risks and uncertainties, including those
discussed below and more fully described in the Securities and Exchange
Commission reports filed by Amgen, including our most recent Form
10-Q. Amgen conducts research in the biotechnology/pharmaceutical
field where movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate
will be successful and become a commercial product.
Furthermore, our research, testing, pricing, marketing
and other operations are subject to extensive regulation by domestic
and foreign government regulatory authorities. In addition, sales
of our products are affected by reimbursement policies imposed by
third party payors, including governments, private insurance plans
and managed care providers. These government regulations and reimbursement
policies may affect the development, usage and pricing of our products.
In addition, while we routinely obtain patents for
our products and technology, the protection offered by our patents
and patent applications may be challenged, invalidated or circumvented
by our competitors.
Because forward-looking statements involve risks and
uncertainties, actual results may differ materially from current
results expected by Amgen. Amgen is providing this information as
of May 31, 2002 and expressly disclaims any duty to update information
contained in this press release.
Amgen is a global biotechnology company that discovers,
develops, manufactures and markets important human therapeutics
based on advances in cellular and molecular biology.
# # #
Amgen, Thousand Oaks
Jeff Richardson, 805/447-3227 (media)
Cary Rosansky, 805/447-4634 (investors)